Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zidovudine (also known as AZT) is a nucleoside analogue reverse transcriptase inhibitor (NRTI) used in the management and treatment of HIV-1 infection. It was the first antiretroviral medication approved for HIV/AIDS and is typically used in combination with other antiretrovirals. Zidovudine works by inhibiting the enzyme reverse transcriptase that HIV uses to make DNA from its RNA, thereby reducing viral replication. It is indicated for slowing disease progression in patients with advanced or early symptoms of HIV infection and for preventing mother-to-child transmission during pregnancy and birth[1][4][5]. The drug does not cure or prevent HIV infection or AIDS but helps lower viral load and supports immune function[1][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zidovudine.